HRDsig positivity was most prevalent in stage I-III (N = 321) and IV (N = 216) TNBC 30.8% and 38.4%, respectively, followed by HR+/HER2− stage I-III (N = 466) and IV (N = 463) cancers 16.7% vs 17.7%, and HER2+ stage I-III (N = 95) and IV (N = 78) cancers 5.3% and12.8%. The gene discussed is ERBB2; the disease is cancer.